Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

• Status: Completed
• Trial end date: 2012-06-01

Summary

The primary objective of this study is to assess the effect of treatment with bendamustine on cardiac repolarization as reflected by the rate-corrected QT interval by the Fridericia method (QTcF).

• Phase: Phase 3

Details

• Lead Sponsor: Cephalon
• Treatments: Bendamustine Hydrochloride; Rituximab